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Introduction: The prion protein (PrP) binds to various molecular partners, but little is known about their potential
impact on the pathogenesis of prion diseases
Results: Here, we show that PrP can interact in vitro with acetylcholinesterase (AChE), a key protein of the cholinergic
system in neural and non-neural tissues. This heterologous association induced aggregation of monomeric PrP and
modified the structural properties of PrP amyloid fibrils. Following its recruitment into PrP fibrils, AChE loses its enzymatic
activity and enhances PrP-mediated cytotoxicity. Using several truncated PrP variants and specific tight-binding AChE
inhibitors (AChEis), we then demonstrate that the PrP-AChE interaction requires two mutually exclusive sub-sites in PrP
N-terminal domain and an aromatic-rich region at the entrance of AChE active center gorge. We show that AChEis that
target this site impair PrP-AChE complex formation and also limit the accumulation of pathological prion protein (PrPSc) in
prion-infected cell cultures. Furthermore, reduction of AChE levels in prion-infected heterozygous AChE knock-out mice
leads to slightly but significantly prolonged incubation time. Finally, we found that AChE levels were altered in prion-
infected cells and tissues, suggesting that AChE might be directly associated with abnormal PrP.
Conclusion: Our results indicate that AChE deserves consideration as a new actor in expanding pathologically relevant PrP
morphotypes and as a therapeutic target.
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The prion protein (PrP) plays a key role in the pathogenesis
of transmissible spongiform encephalopathies, also known
as prion diseases [1,2]. These fatal and infectious neurode-
generative conditions are caused by prions, which consist
mainly, if not exclusively, of misfolded pathological con-
formers (PrPSc) of the host cellular PrP isoform (PrPC) [3].
While the massive contribution of PrP conformational
changes to the etiology of prion diseases is widely recog-
nized, less is known about the role of other molecules that
interact directly with PrP. The large number of potential
PrPC-interacting molecules [4-7] suggests that PrPC, which* Correspondence: joan.torrent@inserm.fr
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unless otherwise stated.is preferentially localized in lipid rafts, is a key member of a
multi-protein complex at the plasma membrane. Moreover,
results obtained using the protein misfolding cyclic amplifi-
cation procedure are consistent with an essential role of
auxiliary macromolecules in PrP conformational rearrange-
ments, leading to prion infectivity and strain maintenance
[8-10]. It is therefore reasonable to hypothesize that in
specific cellular environments in the nervous and lympho-
reticular systems, interaction with a common molecular
partner might promote the selection and enrichment of
thermodynamically and conformationally unique PrP mor-
photypes among the plethora of structurally distinct species
predicted by the high-dimensional PrP folding energy land-
scape [11]. These PrP morphotypes may lie at the origin of
prion diseases.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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structural changes and morphotype selection, we focused
on acetylcholinesterase (AChE), a widely distributed protein
in mammalian tissues and fluids with a large spectrum of
functions. Like PrPC, AChE essentially concentrates in the
lipid raft fraction of the plasma membrane and is found in
two different tissues where prion can be replicated: the syn-
aptic terminals in cholinergic and non-cholinergic brain
areas and reticuloendothelial cells of lymphoid organs
[12,13]. There is compelling evidence that beyond the
well-known hydrolysis of the neurotransmitter acetylcholine
in cholinergic synapses, AChE exerts a variety of less-
characterized “non-classical” roles (attributed to a non-
enzymatic activity or to its cholinergic action in non-neural
tissues) in stress responses and immunity, neuritogenesis
and neurodegeneration [14-17]. Indeed, AChE might con-
tribute to Alzheimer’s disease (AD) pathogenesis through its
ability to interact with amyloid β (Aβ) and to increase neur-
onal death [18-20], the amyloid burden and cognitive defi-
cits in mice [21,22]. Aβ pro-aggregating activity appears to
be mediated by the peripheral anionic site (PAS) of AChE
[23], located at the mouth of a 20 Å deep narrow gorge, at
the bottom of which is placed the catalytic site [24,25].
Hence, AChE inhibitors (AChEis), designed to interact with
both the active and PAS sites of AChE, strongly inhibit not
only AChE catalytic activity, but also AChE-induced Aβ as-
sembly [26-29]. Recent evidence indicates that AChE also
mediates the assembly of two synthetic peptide fragments
spanning residues 106–126 and 82–146 of PrP and that
these interactions are impaired by AChEis that specifically
bind to the PAS site [30,31]. Nevertheless, the influence of
AChE in full-length PrP conformational changes, and its
functional link to prion replication and pathogenesis remain
to be determined. Here we addressed the hypothesis that a
broader non-enzymatic function of AChE in PrP misfolding
and aggregation could be relevant in prion diseases. Indeed,
reduced AChE activity in lumbar CSF samples and altered
AChE glycosylation in the brain and CSF samples of patients
with Creutzfeldt-Jakob disease (CJD) have been observed
[32,33]. Therefore, we investigated the role of AChE in prion
pathogenesis, focusing both on its effect on PrP aggregation
and PrP-mediated toxicity. First we found that two estab-
lished AChEis hindered PrPSc accumulation in cell cultures.
Using biophysical and biochemical approaches, we then
demonstrate that AChE binds to both monomeric and
amyloid fibril conformers of full-length recombinant PrP.
We show that the resulting hetero-assemblies have higher
cytotoxicity. Once recruited into PrP fibrils, AChE loses its
enzymatic activity. The use of different truncated PrP
variants revealed that AChE directly interacts with PrP
N-terminal domain. Through AChEi reduction of AChE
binding to both PrP conformers, we demonstrate that an
aromatic-rich hotspot in the AChE active center gorge en-
trance is involved in the formation of the heterologouscomplex. Moreover, reduced AChE levels in prion-infected
heterozygous AChE knockout (AChE+/−) mice led to signifi-
cantly longer survival compared to wild type controls. Fi-
nally, we found that AChE levels were altered in brain and
spleen of prion-infected mice and also in infected cell cul-
tures compared to non-infected controls.
Materials and methods
Recombinant PrP and AChE
Full-length human PrP and different His-tagged truncated
forms (Δ23-99, Δ100-120, Δ23-99, Δ121-231 and Δ23-120)
were produced in Escherichia coli and purified as described
previously [34]. Purified monomeric PrPs were stored lyoph-
ilized and recovered in the desired buffer by elution through
a G25 desalting column (GE Healthcare). Full-length human
AChE was expressed in Chinese hamster ovary (CHO) cells
and purified from cell culture medium as described previ-
ously [35]. Purified dimeric AChE was concentrated using a
centricon-30 ultrafiltration micro-concentrator from Ami-
con (Millipore Corporation, Billerica, MA, USA) and stored
at 4°C. All concentrations given for fibrillar PrP and dimeric
AChE refer to the respective equivalent monomer
concentration.
AChEis
Racemic huprine Y and Hup8TH were prepared in the
form of hydrochloride salts as previously described [36,37],
whereas tetrahydroaminoacridine hydrochloride (tacrine),
huperzine A and propidium iodide were purchased from
Sigma-Aldrich.
Cell culture
MovS6 cells are immortalized neuroglial cells isolated
from transgenic mice that express ovine PrP [38]. Cells
were grown in Opti-MEM medium with L-glutamine
supplemented with 10% fetal calf serum, 1% penicillin–
streptomycin. Cell cultures were infected at 80% conflu-
ence in 12-well plates with the 127S strain of sheep
scrapie (50 ml of 0.2% (w/v) brain homogenate of
terminally ill tg338 mice in 2 ml of culture medium) as
described in [39]. Four days after exposure, cells were
carefully rinsed and passaged at a 1:10 dilution in 25-
cm2 flasks (passage 1). Cells were further incubated and
diluted 1:10 at each following passage.
PrPSc clearance assay and immunoblotting
Infected MovS6 cells (~106/25 cm2 flasks) were incubated
with various AChEis at different final concentrations for
6 days. At confluence, cells were lysed and treated as
described in [38]. Cell viability was assayed using the (3-
[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazolium bromide;
thiazolyl blue) MTT reduction assay (Sigma-Aldrich) ac-
cording to the manufacturer’s instructions. Western blotting
was performed according to standard procedures. The
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peat domain, was used to detect PrPC; the Sha31 monoclo-
nal antibody (epitope 148–159) [40] was used to detect
PrPres on immunoblots. Detection of AChE was done as de-
scribed above using a rabbit anti-AChE antibody [41]. To
confirm equal protein loading, membranes were also probed
with the anti-b-actin antibody clone AC-74 (Sigma-Aldrich).
Band intensity for PrPSc was measured using the GeneTools
software after acquisition of chemiluminescent signals with
a GeneGnome digital imager (Syngene).
Formation of amyloid fibrils
PrP amyloid fibrils were formed using the manual setup
protocol described previously by [42]. Fibril formation was
monitored using a ThT binding assay [42]. Samples were di-
alyzed in 10 mM sodium acetate, pH 5.0. Then fibrils were
collected by ultracentrifugation and resuspended in 10 mM
sodium acetate, pH 5.0. A washing step was performed by
repeating the ultracentrifugation and resuspension steps.
Transmission Electron Microscopy (TEM)
Samples were deposited on Formvar carbon-coated grids,
negatively stained with freshly filtered 2% uranyl acetate,
dried and viewed using a JEOL 1200EX2 electron micro-
scope (JEOL USA, Inc, Peabody, USA). For immunogold
labeling, samples adsorbed onto grids and air-dried were
washed with H2O. Non-specific binding was blocked by
incubation in PBS with 1% (w/v) bovine serum albumin
(BSA) for 15 min. Grids were then placed onto a droplet
of H-134 anti-AChE polyclonal antibody (Santa Cruz Bio-
technology, Inc. Heidelberg, Germany) diluted 1/25 in
PBS with 1% (w/v) BSA for 1 h. Grids were then washed
in three droplets of PBS with 1% (w/v) BSA (4 min/each)
and placed on a droplet of anti-rabbit IgG conjugated to
10 nm colloidal gold particles for 45 min (Sigma-Aldrich)
diluted 1/50 in PBS with 0.1% (w/v) BSA. Before viewing,
grids were washed with H2O and negatively stained with
freshly filtered 2% uranyl acetate.
Fluorescence measurements
Fluorescence measurements were performed at 20°C using a
FP-6200 fluorimeter (Jasco France, Bouguenais, France). Ali-
quots of each protein sample were incubated with 10 μM
thioflavin T (ThT) for 1 min or 50 μM 8-anilino-1-naphtha-
lene sulfonate (ANS) at room temperature for 10 min before
fluorescence measurements. For ANS spectra, excitation
was at 385 nm. ThT emission spectra were recorded after
excitation at 450 nm. The excitation and emission slit widths
were 4 nm.
Static light scattering (SLS)
Static light scattering kinetic experiments were performed
with a homemade device using a 407-nm laser beam. Light-
scattered signals were recorded at a 112° angle. Signals wereprocessed with a homemade MatLab program. This tech-
nique was coupled with size-exclusion chromatography, to
estimate the absolute molecular weight of AChE (oligomeric
state) using the relationship between the intensity of light
scattered by the molecule and its molecular weight and con-
centration, as described by the Rayleigh theory. A 60 ×
0.78 cm TSK4000SW column (Tosoh Bioscience, Worces-
tershire, UK) was used with 20 mM Mes pH 6.0 as elution
buffer. The temperature of the column was maintained at
18°C. Carbonic anhydrase was used as standard protein for
calibration purposes.
Differential scanning calorimetry (DSC)
Differential scanning calorimetry experiments were per-
formed using a VP-DSC MicroCalorimeter device (GE
Healthcare) with a temperature scan rate of 1°C/min.
Thermograms were recorded using 50 μM PrP in the
presence or not of 50 μM Hup8TH. To ensure reversible
thermal denaturation conditions, 10 mM sodium citrate
pH 4.6 was used.
BS3 cross-linking experiments
Cross-linking was induced at 25°C by the addition of BS3
(500 μM final concentration) (Thermo Fisher Scientific,
Rockford, IL, USA) in a solution of 10 μM PrP, 5 μM AChE
or a mix of both proteins in 20 mM Hepes, pH 7.0. Reac-
tions were stopped after 10 min by adding an excess of
amine groups with 50 mM Tris–HCl buffer. After addition
of Laemmli buffer, samples were heated at 100°C for
10 min and separated by SDS-PAGE on 12% Criterion™ XT
Bis-Tris Precast Gels (Bio-Rad) followed by silver staining.
Fibril annealing and PK digestion assay
PrP fibrils in the presence or absence of AChE were
treated as described previously [43]. Samples were heated
in denaturing sample buffer (60 mM Tris–HCl, 2% SDS,
5% β-mercaptoethanol, 2.25 M urea) at 95°C for 15 min
and separated on 12% Criterion™ XT Bis-Tris Precast Gels
(Bio-Rad) followed by silver staining. Quantification of
protein-band intensities was performed by densitometric
analysis using NIH ImageJ software (National Institutes of
Health, Bethesda, MD).
Primary neuronal cells
Primary cell cultures of neurons were derived from the
cerebral cortex of 17.5 E mouse embryos and carried out
as reported previously [44]. 20 μM of recombinant PrP
isoforms (soluble, fibrils) were pre-incubated in 10 μM
AChE at 37°C for 30 minutes before their addition to
the cells at a final concentration of 1 and 0.5 μM, re-
spectively. After 72 hours in vitro, the cytotoxic effect of
each treatment was analyzed by fixing cells in 4% para-
formaldehyde solution and staining with Hoechst 33258.
Apoptotic cells were identified by the characteristic
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mented chromatin. Neurons were identified with a primary
mouse anti-beta 3 tubulin antibody (1:400; Sigma-Aldrich)
and revealed by staining with an anti-mouse Cy3 secondary
antibody (1:400; Jackson ImmunoResearch Europe Ltd.,
Suffolk, UK). Digital images were captured from 10 random
fields for each sample (≈3500 cells total) using an Axiovert
200 M Zeiss inverted microscope (Carl Zeiss S.A.S., Marly
le Roi, France). Neuronal cell death was determined by
counting the bright neurons and expressed as the percent-
age of the total cell number compared with control cul-
tures. Data were analyzed by one-way analysis of variance
and a Tukey test was carried out on the results of four inde-
pendent experiments.
Inhibition of AChE enzymatic activity
7.3 nM AChE was mixed with PrP fibrils (concentration
ranging from 8 to 25 μM) or 25 μM monomeric PrP at
37°C in 100 mM sodium phosphate buffer pH 7.4 contain-
ing 0.33 mg/mL BSA. The residual activity contained in a
10-μL aliquot was monitored at 25°C and pH 7.4, accord-
ing to the Ellman’s method, using 1 mM acetylthiocholine
and 0.5 mM dithiobisnitrobenzoic acid and a final volume
of 200 μl.
Ethics statement
Animal experiments were carried out in strict accordance
with the EU directive 2010/63 and were approved by the
authors’ institution local ethics committee (Comethea; per-
mit number 12/034).
Infection of tg338 mice with LA21K fast prions
The cloned ovine prion strain LA21K fast used in this study
has been previously described [45]. Individually identified 6
to 10 week/old tg338 mice were inoculated intracerebrally
with 20 μl of 10% (w/v) infected brain homogenates (pre-
pared in 5% glucose) (n = 5 mice). Age-matched control
tg338 mice received uninfected brain homogenates (n = 5
mice). Mice showing prion-specific neurological signs were
monitored daily and euthanized at the terminal stage of
prion disease. At this time point, control mice were also eu-
thanized. After perfusion with physiological saline and eu-
thanasia, half-brain specimens were dissected into two parts:
a cortex-enriched fraction and a fraction containing the
remaining brain areas. These samples were flash frozen, and
stored at −80°C. Spleens were also rapidly removed, flash
frozen, and stored at −80°C.
Infection of AChE+/− and AChE+/+ mice with 139A prions
AChE+/− mice (Xie et al. 2000) and wild type (AChE+/+) lit-
termates were maintained by breeding heterozygous males
and females (129/Sv genetic background). Individually iden-
tified, 6 week/old mice were infected by intracerebralinoculation with 20 μl of a 0.1% (w/v) 139A mouse scrapie
strain, as described above.Tissue homogenization
Brain and spleen tissues (10% (w/v) and 5% (w/v), respect-
ively) were homogenized using a Rybolyser Precellys (Bertin
Technologies, Montigny-le-Bretonneux, France) and ice-
cold extraction buffer (25 mM Tris–HCl, 150 mM NaCl,
pH 7.3) containing 1% Triton X-100 and protease inhibitors
(10 mM EDTA, 40 μg/ml leupeptin, 10 μg/ml pepstatin
and 2 mM benzamidine). Extracts were incubated on ice
for 1 h and then centrifuged at 30,000 × g for 30 min. The
protein content of supernatants was determined using the
Bicinchoninic acid assay reagent kit (Pierce Biotechnology,
Rockford, USA).Detection of PrPSc in brain and spleen
Before the centrifugation step of the homogenization pro-
cedure, PrPSc was extracted with the BioRad TsSeE purifi-
cation and detection kit (Marnes-la-Coquette, France) and
digested with 200 μg/ml proteinase K (Euromedex, Mun-
dolsheim, France) at 37°C for 10 min. After denaturation in
Laemmli buffer at 100°C for 5 min, samples were run on
12% Criterion™ XT Bis-Tris Precast Gels (Bio-Rad), electro-
transferred to nitrocellulose membranes, and probed with
the biotinylated anti-PrP monoclonal antibody Sha31, as
previously described [46]. Immunoreactivity was visualized
by chemiluminescence (GE Healthcare, Orsay, France).AChE detection in brain and spleen
200 mg of total proteins were separated on 7.5% Criter-
ion™ TGX™ Gels (Bio-Rad) in reducing conditions, and
then transferred to nitrocellulose membranes. Blots were
blocked in Tris-buffered saline (TBS) with 0.5% Tween
20 (TBS-T) containing 5% nonfat dried milk at 4°C over-
night before incubation with a rabbit anti-AChE anti-
body [41], (1:2000 in the same TBS-T buffer) at 4°C
overnight. Blots were then incubated with peroxidase-
conjugated anti-rabbit IgG antibodies (1:10,000; Abliance
SAS, Compiègne, France) at room temperature for
30 min, washed extensively and exposed to the chemilu-
minescent substrate ECL Plus (GE Healthcare). The
amount of AChE present in each tissue was determined
with the GeneTools software after acquisition of the
chemiluminescent signals with a GeneGnome digital
imager (Syngene, Frederick, Maryland, USA). To con-
firm equal protein loading, membranes were also probed
with an anti-β-actin (clone AC-74; Sigma-Aldrich, Saint-
Quentin Fallavier, France), or anti-GAPDH antibody
(Chemicon International, Temecula, USA). AChE pro-
tein values were normalized by the corresponding β-
actin and GAPDH protein content.
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Total AChE activity in the homogenates was assayed
using 1 mM acetylthiocholine and 0.5 mM 5,5-dithiobis
(2-nitrobenzoic acid) (DTNB) in the presence of 50 μm
tetra(monoisopropyl)pyrophosphortetramide (iso-OMPA)
(Sigma-Aldrich). Extracts were first incubated in the ab-
sence of acetylthiocholine for at least 20 min to block bu-
tyrylcholinesterase and saturate the free sulfhydryl groups
that interact with DTNB. Changes in optical density were
measured at 414 nm.
RNA extraction and RT-qPCR
Total RNAs were extracted from spleen and brain sam-
ples after homogenization in RLT buffer (RNeasy kit,
Qiagen) and QIAzol Lysis Reagent (Qiagen), respect-
ively, following the manufacturer’s recommendations.
Reverse-transcriptions were performed using the Super-
script reverse transcriptase (Invitrogen) and random
hexamers (Fermentas). The levels of choline acetyltrans-
ferase (ChAT) transcripts and of alternatively spliced
AChE transcripts were measured using the Mastercycler
realplex sequence detector (Eppendorf ) and the double
stranded DNA-specific dye SYBR Green system (Applied
Biosystems) with the following primers: AChE (exon2)
sense 5′-GCATACACCTTCCCTGGCTT-3′, antisense 5′-
AAAAGCTGAGACTGGGCCTC-3′; AChE-E sense 5′-
TCAGCGCCACCGCCACGGAG-3′, antisense 5′-AGAG
GAGGGACAGGGCTAAG-3′; AChE-S sense 5′-TGTGA
GCCTGAACCTGAAGC-3′, antisense 5′-CTGGTTCTTC
CAGTGCACCA-3′; AChE-R sense 5′-TCAGCGCCACC
GGTAGGCGC, antisense 5′-AGAGGAGGGACAGGGC-
TAAG-3′; ChAT sense 5′-AAATGGCGTCCAACGAGGA
T-3′, antisense 5′-GCTCGATCATGTCCAGGGAG-3′; H
PRT sense 5′-GGTTAAGCAGTACAGCCCCA-3′, anti-
sense 5′-TCCAACACTTCGAGAGGTCC-3′. PCR condi-
tions and cycles were as follows: initial DNA denaturation
at 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec,
then an annealing step at 60°C for 15 sec, and finally an ex-
tension step at 72°C for 30 sec. To ensure that the primers
produced a single and specific PCR amplification product,
a dissociation curve was performed at the end of each PCR
assay. Relative quantification was performed by using the
comparative ΔΔCt method. The mean ΔCt obtained using
samples from mock-infected mice for each isoform was
used as calibrator after normalization to the endogenous
control hypoxanthine-guanine phosphoribosyltransferase
(HPRT). Results are presented as n-fold difference relative
to the calibrator (RQ= 2-ΔΔCt).
Results
The potent tight-binding AChEis huprine Y and Hup8TH
limit PrPSc accumulation in prion-infected cell cultures
First we asked whether AChE actively participates in PrPSc
accumulation. We thus investigated the effect of AChEinhibition in prion-infected MovS6 cells [38], a model pre-
viously used in proof of principle studies on candidate anti-
prion agents [47,48]. We chose the high-affinity reversible
AChEis huprine Y (a huperzine A-tacrine hybrid) [36,49]
and Hup8TH (a huprine-tacrine heterodimer) [37], based
on their extremely potent inhibition of AChE catalytic ac-
tivity and particularly their ability to impair AChE-induced
aggregation of Aβ and PrP peptides [30,31]. In parallel, we
also tested the parent compounds tacrine and huperzine A,
as well as propidium iodide, a specific AChE PAS inhibitor.
Western blot analysis after PK digestion of crude extracts
from confluent, prion-infected MovS6 cells cultured in the
presence of 20 μM of each AChEi or vehicle alone for 6 days
showed that only huprine Y inhibited PrPSc accumulation
(Figure 1a). As Hup8TH was cytotoxic at this concentra-
tion, we repeated the experiment with non-cytotoxic doses
(0.1 to 0.5 μM). Hup8TH treatment reproducibly led to
PrPSc level reduction and this effect was dose-dependent
(Figure 1b). These results reveal that AChEis limit PrPSc
accumulation in an AChE-binding depending manner, i.e.
tacrine (no effect) < huprine Y <Hup8TH. For Hup8TH, fit-
ting of the dose–response curve (Figure 1c) yielded a 50%
inhibitory concentration (IC50 value) of approximately
0.22 ± 0.01 μM. The toxicity of Hup8TH was assessed
using the MTT metabolic assay (Figure 1c). Cell viability
decreased by approximately 10% at concentrations of
Hup8TH required for maximal inhibition of PrPSc accu-
mulation. In uninfected MovS6 cells, PrPC expression
levels were unaffected by 0.5 μM Hup8TH (Figure 1d),
ruling out the possibility that Hup8TH inhibition of PrPSc
accumulation in infected culture was due to an altered
steady state level of PrPC.
AChE binds to PrP monomers and induces their
aggregation
To determine whether a direct AChE/PrP interaction
could explain these results, we performed SLS measure-
ments of full length PrP mixed with increasing AChE con-
centrations (Figure 2a). The raise in scattering intensity
upon mixing the two proteins (time zero) indicated an in-
crease in the average molecular weight of the sample, sug-
gesting the formation of AChE:PrP complexes. After
strengthening the ionic character of the buffer by adding
200 mM NaCl, the reaction was readily detected even at
the molar ratio of 1.25:100 (AChE:PrP), confirming the
interaction specificity (Figure 2b). TEM also supported
AChE positive effect on PrP aggregation by showing that
larger PrP assemblies were formed in the presence of
AChE than in its absence (Figure 2c).
To assess whether the aggregates (identified by SLS)
resulting from the interaction between PrP and AChE
contained both proteins, we fractionated the solutions into
supernatant (S) and pellet (P) fractions by ultracentrifuga-
tion and separated them by SDS-PAGE (Figure 2d). PrP
Figure 1 The tight-binding AChEis huprine Y and Hup8TH efficiently decrease PrPSc accumulation in Scrapie-infected MovS6 cells.
a Scrapie-infected MovS6 cells were incubated with 20 μM of the indicated AChEis for 6 days and then lysed. PrPSc accumulation was determined
by using the anti-PrP antibody Sha31b; the anti-β-actin antibody was used to control protein loading. Ctr, vehicle-treated cells. b Prion-infected
MovS6 cells were incubated with 0.5 μM Hup8TH or 0.1 to 0.5 μM Hup8TH and then processed as in a. c Densitometric measurement of PrPSc
signal, expressed as percentage relative to the untreated control (closed circles). Results are expressed as the mean ± SD of three different
experiments. Cell viability determined by using the MTT assay is also shown (open circles). The absorbance values are expressed as the mean
± SD of four independent experiments relative to the absorbance values of the untreated control. Solid and dashed lines are fits to the data.
d Protein lysates from uninfected MovS6 cells were analyzed by immunoblotting without proteinase K digestion. The effect of Hup8TH on PrPC
accumulation was determined using the SAF32 antibody. Molecular weights (in kilodaltons) are indicated on the left of the blots.
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mixing, 10-20% of the total content was present in the
pellet.
To further substantiate AChE-PrP interaction, we
then performed chemical crosslinking using the amine-
to-amine cross-linker BS3 followed by SDS-PAGE
(Figure 2e). After crosslinking, PrP and AChE alone
showed a unique band that corresponded to the mono-
meric protein. Conversely, in the mix, an additional
band was visible and its molecular weight was consist-
ent with the assembly of one PrP monomer with one
AChE monomer.
To characterize the specific regions within the PrP
molecule that are crucial for AChE binding, we gener-
ated various PrP truncated variants (Figure 2f ). In the
absence of the largely unstructured N-terminal region
of PrP (residues 23–120), AChE-mediated aggregate for-
mation was abrogated. All other PrP variants allowed
aggregation, albeit with varying efficacy. These results
led us to conclude that AChE directly interacts with PrP
unstructured N-terminus and more precisely with two
mutually exclusive sub-sites that are included between
residues 23 and 99 and residues 100 and 120.Hup8TH reduces AChE-induced aggregation of PrP
We then assessed whether Hup8TH, the most potent
anti-PrPSc AChEi in cell culture, could interfere with
AChE-PrP interaction, and consequently reveal the exist-
ence of a hot spot in AChE for the binding interface. To
this aim, we pre-incubated AChE with Hup8TH at molar
ratios up to 1:25 (AChE:Hup8TH) at room temperature
for 30 min and then added the solution to monomeric
PrP (time zero). SLS measurements (Figure 2g) indicated
that Hup8TH inhibited the aggregation by approxi-
mately 50% at the highest dose tested. The compound
had no effect on the monitored light scattering of PrP
and AChE alone. In addition, to test whether the inhibi-
tory activity of Hup8TH relied on an unexpected direct
interaction with PrP, we measured the heat-induced PrP
equilibrium unfolding by DSC. To this purpose, we used
PrP at pH 4.6, which allows studying the reaction as a
reversible two-step process [50]. DSC thermograms of
PrP in the absence and in the presence of Hup8TH at
equimolar concentration showed no difference in the
single endothermic peak typical of protein denaturation
(Additional file 1), indicating that Hup8TH does not dir-
ectly interact with PrP.
Figure 2 (See legend on next page.)
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Figure 2 The formation of an aggregation-prone complex via specific interaction of AChE with PrP N-terminal domain is partially inhibited
by Hup8TH. a Kinetics of AChE-PrP assembly. Increasing concentrations of AChE were added to 5 μM PrP. AChE:PrP molar ratios are indicated next to
the trace. The extent of protein aggregation was recorded by light scattering intensity (also in panels b, f and g). The results for AChE in the absence
of PrP are not shown because they overlap with the kinetic profile of PrP alone. b Probing the specificity of the interaction by strengthening the ionic
character of the buffer. AChE was added to 20 μM PrP in the presence of 200 mM NaCl. The AChE:PrP molar ratios are indicated next to the trace. The
asterisk shows the kinetic profiles of AChE (lower curve) and PrP (higher curve) alone. c Negative-stained transmission electron micrographs of AChE
(upper left panel), PrP (upper right panel) and a mix of both proteins (lower panel). The molar ratio used was 0.5:1 (AChE:PrP). Scale bar = 250 nm.
d The presence of both PrP and AChE in the insoluble fraction (pellet, P) after centrifugation of a mixture of 10 μM PrP with 5 μM AChE (incubated at
37°C for 30 min) confirms the formation of PrP-AChE aggregates. Gels were stained with Coomassie Blue. S, soluble fraction. e BS3 cross-linking assay
demonstrates the formation of a heterodimer. Silver-stained gel showing PrP (10 μM), AChE (5 μM), and a mix of both proteins after incubation with
500 μM BS3. f Importance of the PrP N-terminus for the heterologous interaction. Left panel: schematic representation of the various PrP constructs.
Right panel: kinetics of AChE assembly with truncated PrP variants. 50 nM AChE was added to 2 μM PrP variants (the full-length PrP profile is shown as
grey line). The vertical dotted line indicates when AChE was added (time zero). g Hup8TH decreases AChE binding to PrP. AChE was pre-incubated at
room temperature with increasing concentrations of Hup8TH for 30 min (AChE:Hup8TH molar ratios from 1:0.6 to 1:25). Then, 250 nM PrP was
incubated with 50 nM pre-treated or not (grey line) AChE (AChE:Hup8TH molar ratios are indicated next to the trace). The asterisk highlights the kinetic
profiles of AChE and PrP alone incubated with the highest Hup8TH concentration. h The effect of Hup8TH on AChE-PrP co-aggregation was monitored
by Coomassie blue staining after SDS-PAGE. 10 μM PrP and 5 μM AChE were incubated or not at 37°C with Hup8TH (1:100 molar ratio, AChE:Hup8TH)
for 30 min. Supernatant and pelleted fractions obtained after centrifugation were analyzed. Experiments were performed in 20 mM Mes buffer (pH 6.0)
at 37°C; a.u., arbitrary units. Molecular weights (in kilodaltons) are indicated to the left of the blots.
Figure 3 Macrostructure of the AChE-PrP fibril morphotype.
Negative-stained transmission electron micrographs of PrP fibrils
formed in the absence (left panels) or presence (right panels) of
AChE, after direct deposition onto a grid (a), or following incubation
with an anti-AChE antibody and a secondary antibody conjugated
to 10-nm gold nanoparticles (b). The molar ratio used was 0.5:1
(AChE:PrP). All scale bars are 100 nm.
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on AChE-PrP aggregation, we separated samples into pel-
let and supernatant fractions by ultracentrifugation. SDS-
PAGE analysis (Figure 2h) showed that pre-treatment of
AChE with Hup8TH practically suppressed the aggrega-
tion effect. Moreover, binding of Hup8TH to AChE did
not alter the enzyme solubility, excluding any decrease in
the soluble AChE pool available for interaction with PrP.
These results validate the specificity of the AChE-PrP
hetero-assembly and provide strong evidence for the ex-
istence of a hotspot on AChE for PrP binding that can
be targeted successfully by a small inhibitor molecule.
AChE associates with PrP fibrils
We then studied whether PrP fibril structure could be
modulated by AChE. The enzyme did not affect the fibril-
formation process promoted by partially-denaturing solvent
conditions (2 M guanidine-HCl). Nevertheless, fibrils
formed from a mix of AChE and PrP (0.5:1 ratio) (Figure 3a,
right panel) were decorated by punctuate material, probably
the co-assembled AChE, when compared to fibrils obtained
from PrP alone (Figure 3a, left panel).
To confirm the presence of AChE in PrP fibrils, we used
immuno-electron microscopy and an anti-AChE antibody
that was revealed with a secondary antibody conjugated to
10-nm gold nanoparticles (Figure 3b). Only in fibrils
formed in the presence of AChE, electron-dense gold nano-
particles colocalized with PrP fibrils (Figure 3b right panel),
demonstrating the interaction of AChE with the fibrils. The
AChE-PrP assembly obtained in mild denaturing condi-
tions highlights the specificity of the reaction.
Next, to assess whether AChE could bind also to ma-
ture pre-formed PrP fibrils, we incubated AChE with
preformed PrP fibrils at 37°C for 30 min. After centrifu-
gation, AChE co-sedimented with PrP fibrils (Figure 4a).Analysis by TEM of the macrostructure of this AChE:
PrP fibril complex revealed thicker fibrils, compared to
PrP fibrils alone, suggesting that AChE homogenously
coats the filaments (Additional file 2).
We then evaluated whether AChE binding affected some
generic physical properties of PrP amyloid fibrils. First, we
used the fluorescence probe ANS to study the presence of
hydrophobic clusters on the PrP fibrillar surface (Figure 4b).
ANS binding to PrP fibrils resulted in higher fluorescence
yield and a blue shift in the fluorescence spectrum, as ex-
pected for PrP fibril structures, compared to the weak
Figure 4 AChE associates with amyloid fibrils via the PrP N-terminus and affect their physical-chemical characteristics. This association is
inhibited by Hup8TH. a Co-aggregation of AChE with preformed PrP fibrils (Fib PrP) was followed by Coomassie blue staining after SDS-PAGE of
10 μM Fib PrP mixed with 5 μM AChE at 37°C for 30 min. b AChE increases ANS binding to preformed PrP fibrils. ANS fluorescence emission
spectra of monomeric PrP protein (dotted line), untreated PrP fibrils (long dashed line), fibrils after AChE association (short dashed line) and AChE
alone (solid line). Samples correspond to either supernatant or pelleted fractions obtained after centrifugation. Final protein concentrations:
10 μM PrP, 5 μM AChE. Incubation conditions: 37°C for 30 min. c Altered digestion profile of the PK-resistant core of PrP fibrils after AChE binding.
Silver staining following electrophoretic separation of PrP fibrils (10.5 μM ) incubated or not with AChE (0.5 μM), before and after PK digestion
(+PK). The annealing procedure involves brief heating of the sample at 80°C in the presence of detergent. d Kinetics of AChE-PrP fibril
co-assembly. Light scattering intensity was used to follow the increase in the average molecular weight during successive additions (indicated by
an arrowhead) of 25 nM AChE to 50 nM preformed PrP fibrils. The vertical dotted line indicates when AChE was first added (time zero). Saturation
occurs at equimolar concentrations. The profile obtained after a single addition of 50 nM AChE to the fibrillar sample is also shown to emphasize
the equivalent total amplitude change. e AChE interacts with PrP fibrils obtained from two N-terminal truncated PrP variants (Δ100-120 and
Δ23-99) and reaches saturation at half the molar ratio (0.5:1, AChE:PrP), compared to full-length PrP fibrils. Two successive additions (indicated by
an arrowhead) of 25 nM AChE to the two truncated PrP fibrils (50 nM) were performed. f Hup8TH decreases the binding of AChE to PrP fibrils.
AChE was pre-incubated at room temperature with Hup8TH at a molar ratio of 1:20 (AChE:Hup8TH) for 30 min. Then, 50 nM PrP fibrils obtained
from full-length PrP were incubated with 50 nM pre-treated (grey line with asterisk) or non-inhibited AChE (grey line without asterisks). The same
experiment was performed using the two truncated PrP fibrils and with 25 nM (according to the saturation values observed in e) of pre-inhibited
(black lines with asterisks) or not (black lines without asterisks) AChE. Data were normalized between 0 and 1 to easily compare the effects of the
AChEi on the fraction of aggregated AChE. Experiments were performed in 20 mM Mes buffer (pH 6.0) at 37°C; a.u., arbitrary units. Molecular
weights (in kilodaltons) are indicated to the left of the blots.
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PrP [51]. Upon ANS binding to the complex formed be-
tween pre-formed PrP fibrils and AChE, the fluorescence
spectrum was further enhanced and blue-shifted, showing
the presence of additional structured hydrophobic domains.
This spectrum was therefore consistent with the observed
AChE coating of PrP fibrils.
In addition, we carried out PK digestion to assess al-
terations in the PrP PK-resistant core after AChE bind-
ing (Figure 4c). Compared to PrP amyloid fibrils, the low
molecular weight bands in AChE:PrP fibril complexes
were more intense (for a densitometric analysis of the
corresponding bands see Additional file 3), with a sub-
stantial increase of the PK-resistant core and a stronger
~16-kDa PK-resistant band. These differences were fur-
ther substantiated after annealing, a procedure specific
for amyloid PrP structures that induces conformationalrearrangements within PrP fibrils [43]. In the AChE:PrP
fibril complex, the characteristic 16-kDa band was
much intensified, when compared to PrP fibrils alone.
These results are consistent with the gain of structural
and conformational integrity of PrP fibrils after AChE
interaction.
To better understand the mechanism of AChE binding
to the PrP amyloid form, we then performed SLS kinetic
measurements by successively adding 25 nm AChE to
50 nM of pre-formed PrP fibrils (Figure 4d). An increase
in light scattering that reflected the raise in the average
molecular weight of the sample was observed, suggesting
the formation of a stable complex between AChE and fi-
brillar PrP. Moreover, the signal was saturated when the
molar ratio of 1:1 (PrP:AChE) was reached. As expected,
a single addition of an equimolar concentration of AChE
(50 nM) had the same effect.
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fibril interaction, we used SLS to investigate the inter-
action between AChE and two fibrillar samples obtained
from two N-terminally truncated PrP variants lacking ei-
ther residues 23–99 or 100–120, the two mutually exclu-
sive sub-sites for the AChE-PrP interaction that we
previously identified using monomeric PrP. AChE bound
to both truncated fibrils. Nevertheless, and in contrast to
full-length PrP fibrils that contain both sub-sites, the kin-
etic profiles reached a plateau at a molar ratio of 0.5:1
(AChE:PrP) (Figure 4e). A subsequent addition of AChE
did not further increase the average molecular weight of
each fibrillar sample.
Hup8TH reduces AChE-binding to PrP fibrils
To examine whether AChE binding to PrP fibrils depends,
as for monomeric PrP, on the same AChE hotspot that can
be targeted by Hup8TH, we studied by SLS the effect of
Hup8TH on AChE interaction with amyloid fibrils obtained
from full length, Δ23-99 and Δ100-120 PrPs. To this aim,
we pre-incubated AChE with its inhibitor at a molar ratio
of 1:20 (AChE: Hup8TH) at room temperature for 30 min.
Then, we added the mixture to each of the three PrP fibril-
lar forms. Hup8TH strongly inhibited AChE binding to all
PrP fibrils (Figure 4f, traces with asterisks). Moreover,
AChE binding reduction was dependent on the PrP fibrillar
form used and thus on the presence/absence of the two N-
terminal sub-sites that are essential for this heterologous
interaction. The resulting fraction of protein complexes es-
timated for full-length PrP fibrils in the presence of
Hup8TH (~30%) corresponded approximately to the mean
of the values obtained for fibrils formed from the truncated
PrP variants.
The interaction of AChE with PrP fibrils inhibits AChE
enzymatic activity and enhances PrP fibril cytotoxicity
We next determined whether PrP fibrils have any effect
on the enzyme activity by assessing AChE enzymatic ac-
tivity in the absence or presence of 25 μM monomeric
or fibrillar PrP (3500 molar excess) (Figure 5a, left
panel). Whereas no change was observed using mono-
meric PrP, AChE was completely inhibited after 30 min
of incubation in the presence of fibrils. This inhibition
was linearly proportional to the concentration of PrP fi-
brils (Figure 5a, right panel).
Finally, to investigate whether AChE interaction with PrP
increases PrP toxicity we compared the cytotoxicity of sol-
uble monomeric PrP, AChE and of the mix obtained after
30 min incubation, as well as of PrP amyloid fibrils and pre-
formed amyloid fibrils associated with AChE by Hoechst
nuclear staining of primary neuronal cells (Figure 5b).
Monomeric PrP caused only a minor toxic effect, whereas
the complex with AChE was three times more toxic, with a
neuronal cell death rate comparable to that of PrP fibrils.The fibrillar morphotype arising from AChE association
with PrP fibrils showed the highest cytotoxicity.Prion-infected AChE+/− mice display slightly but
significantly increased survival time
We then examined whether partial AChE gene knockdown
in transgenic mice, which reportedly leads to a 25-35% de-
crease in AChE activity [52], could affect prion disease
tempo in vivo. Following intracerebral inoculation of 139A
prions, the mean survival time of AChE+/− mice (160 ±
1 days, n = 9) was slightly but significantly longer than that
of wild type mice (151 ± 3, n = 7)(p = 0.03 Mann–Whitney
U test). However, at the terminal stage of disease, there was
no difference in the brain accumulation and regional distri-
bution of PrPSc in AChE+/− and wild type mice.Prion infection selectively alters AChE levels in vivo and in
cell cultures
We tested whether AChE levels were altered in vivo in re-
sponse to prion infection. We injected brain homogenates
infected or not (mock) with LA21K fast prions in trans-
genic tg338 mice that express ovine PrP (VRQ/VRQ PrP
genotype). At the terminal stage of the disease, we mea-
sured the levels of AChE transcripts, protein and enzymatic
activity in cerebral cortex-enriched homogenates (Figure 6a)
and in the brain fractions containing the remaining struc-
tures (Figure 6b) from each infected mouse (n = 5) and age-
matched mock-infected controls (n = 5).
RT-qPCR quantification showed that AChE mRNA
levels were increased by two-fold in cortical-enriched
extracts of infected mice compared to controls (Figure 6a,
right panel). Conversely, the cholinergic ChAT mRNA
levels were not significantly different (Additional file 4),
suggesting that prion disease affects AChE in a specific
manner. In addition, no difference in the splicing pattern
of the ACHE gene was observed in the two groups. As ex-
pected, AChE-T mRNA (95%) was more abundant than
AChE-R and AChE-H mRNAs (Additional file 4). ACHE
gene up-regulation was accompanied by a comparable
change in AChE protein expression in prion-infected
brains compared to controls (Figure 6a). However, AChE
activity was not increased compared to control mice, sug-
gesting that prion infection causes AChE inhibition in
these brain areas. Indeed, normalization of AChE activity
values to AChE protein content, as estimated by western
blotting, indicated that AChE catalytic activity was de-
creased by nearly 40% in the in cortical-enriched extracts
of infected mice.
In the rest of the brain of infected mice, no increase in
AChE mRNA levels was observed compared to controls
(Figure 6b, right panel), and AChE protein and activity
levels were reduced by 25% (Figure 6b). Therefore, the
normalized AChE activity, calculated based on AChE
Figure 5 The interaction of AChE with PrP fibrils inhibits AChE enzymatic activity and enhances the cytotoxicity of both monomeric
alpha-helix-rich and amyloid fibril PrP conformers in primary neurons. a PrP fibrils inhibit AChE enzymatic activity. Left panel: 7.3 nM AChE was
pre-incubated for different periods of time without (open circles) or with 25 μm of monomeric (open squares) or fibrillar PrP (black circles) before
initiation of the reaction with ACh. Right panel: Decrease in the observed AChE activity as a function of PrP fibril concentration. b Neurons were
cultured for 2 days and then incubated with monomeric (PrP) or fibrillar (Fib) PrP isoforms (final concentration, 1 μM), 0.5 μM AChE or the PrP-AChE
mix. Neuronal cell death was quantified and expressed as the percentage relative to the value of control cells (vehicle). Each set of data is the mean
value ± S.D. (in percentage) of four experiments; five independent microscopic fields were counted for each experiment. **P < 0.005, one-way ANOVA.
The Tukey test was used for post-hoc comparison after ANOVA.
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pared to control mice.
We then investigated whether the extra-cerebral AChE
levels also were altered upon prion infection. We focused
on the spleen, a secondary lymphoid organ in which prions
can replicate and accumulate [53,54]. Despite noticeable
inter-individual variability in the spleens of control mice,
AChE protein level and enzymatic activity were very signifi-
cantly lower (70% and 96% decrease, respectively) in spleen
from infected mice compared to control (Figure 6c). Con-
versely, AChE mRNA levels were not changed compared to
uninfected mice, indicating that AChE depletion during
prion disease occurs via a post-transcriptional process and
may be inherently linked to prion replication.
To investigate whether this phenomenon occurs in vitro
in cultured cells, we examined AChE protein level and en-
zymatic activity in the neuroglial mouse cell line MOVS6
that is persistently infected with the 127S scrapie strain,
which phenotypically resembles LA21K fast prions [45].
Consistent with our findings in the spleen, both AChE
protein and activity levels were reduced in infected cells,
by 66% and 45%, respectively, compared to control mock-
infected cells (Figure 7).
Discussion
Here, we provide conclusive evidence that AChE can be
functionally linked to PrP misfolding. This novel func-
tion of AChE, which is present in the biological environ-
ment where PrP replication may occur naturally, brings
crucial knowledge on prion structural changes and their
potential pathobiological implications. In this work, we
addressed the relationships between the formation of
AChE/PrP hetero-assemblies and i) their cytotoxicity in
primary neuronal cultures, as well as the extended sur-
vival of prion-infected AChE+/− mice; ii) the interferenceof dual-site binding AChE inhibitors with prion accumu-
lation; and iii) the altered AChE homeostasis in both
nervous and lymphoreticular systems of prion-infected
mice and in chronically infected cell cultures.
AChE confers new properties to PrP amyloid fibrils
We show that AChE facilitates PrP aggregation and/or
confers new structural properties to PrP amyloid fibrils.
AChE incorporation into PrP amyloid fibrils substan-
tially increases the PK-resistant core and specifically
leads to a stronger ~16-kDa PK-resistant band, similar
to that of naturally occurring PrPSc and to infectious
synthetic prions [55,56]. This supports the idea that
AChE facilitates a conformational rearrangement in
which the PrP region between residues ~90 and 140
adopts a PK-resistant conformation, which is thought to
be critical for PrP conversion to a PrPSc-like molecule
[43]. In addition, AChE assembly with PrP amyloid
fibrils leads to enhanced hydrophobic exposure and sig-
nificantly higher cytotoxicity in primary cultured neu-
rons, compared to non-complexed PrP fibrils. Elevated
neurotoxicity is also observed when AChE aggregates
with the soluble PrP conformer. Thus, the longer sur-
vival observed in animals with lower AChE activity can
be explained by a reduced amount of cytotoxic PrP
morphotypes. The strongly reduced life expectancy and
other abnormalities of AChE−/− mice [57] currently do
not allow studying the consequences of complete deple-
tion of AChE on prion pathogenesis. It remains to be
investigated whether AChE is present in scrapie-
associated fibrils. Nevertheless, it is unlikely that under
harsh biochemical conditions, such as detergent extrac-
tion and proteinase K digestion used to extract scrapie-
assocaited fibrils [58], PrP will co-purify with potential
binding partners that it complexes with inside the cell.
Figure 6 AChE levels are altered in the brain and spleen of prion-infected mice. Left panels: Western blot analysis of cerebral cortex-enriched
homogenates (a), brain extracts containing the remaining structures (b), and spleen homogenates (c) prepared from tg338 mice expressing ovine PrP
(VRQ/VRQ PrP genotype) and infected with LA21K fast prions or not (controls, Ctr). All inoculated mice (n = 5) developed prion disease, as indicated by
the presence of PrPSc, and showed altered AChE protein levels compared to age-matched, mock-infected controls (n = 5). β-actin or GAPDH levels are
shown as loading control. Molecular weighs (in kilodaltons) are indicated on the left of the blots. Right panels: Vertical bar charts comparing the levels
of AChE transcripts, protein and enzymatic activity in control and infected mice. Values are presented as fold change relative to control mice. Data are
the mean ± SEM obtained from the indicated number of mice. mRNA levels of total AChE transcripts were normalized to HPRT expression in the
same cDNA preparations. Densitometric quantification of AChE protein was normalized to β-actin (brain) or GAPDH (spleen). *P < 0.05, **P < 0.005,
***P < 0.001 compared to controls (one-way ANOVA).
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contribute to the AChE-PrP complex formation
The AChE-PrP interaction might be explained by the
fact that AChE (i.e., each catalytic subunit constituting
the enzyme) displays a very large dipole moment that is
oriented approximately along the axis of the active-site
gorge (Additional file 5a). This particular arrangement,
which has an excess of negative charge on the surface
near the entrance of the AChE catalytic gorge, renders
the protein particularly prone to experiencing promiscu-
ous electrostatic interactions. Therefore, the presence of
an extended disordered N-terminal region with twopositively charged sub-sites (Additional file 5b) in both
the alpha-helix rich PrP monomer and amyloid PrP fi-
brils, might favor interaction with AChE. This heterol-
ogous interaction may partially mask the charge-charge
repulsion between neighboring homo-molecules, thereby
considerably increasing the local concentration of the
protein, and favoring the rapid assembly. The lack of
interaction with the N-terminal truncated PrP Δ23-120
variant further reinforces our hypothesis.
We also explain why dual-site binding AChE inhibitors
are endowed with anti-prion activity. Our in vitro studies
show that the specific tight interaction of Hup8TH
Figure 7 Decreased AChE levels in prion-infected MovS6 cells. a Western blot analysis of AChE levels in infected cells harboring PK-resistant
PrPS. PrPSc accumulation was determined with the anti-PrP antibody Sha31b; the anti-β-actin antibody was used to control protein loading. Ctr,
mock-infected cells. Molecular weights (in kilodaltons) are indicated on the left of the blots. b Quantification of AChE protein (orange bars) and
enzymatic activity (green bars) in mock-infected (Ctr) and prion-infected MovS6 cells. Values are presented as fold change relative to control cells.
Data are the mean ± SEM of four independent experiments for each condition. *P < 0.05 one-way ANOVA.
Torrent et al. Acta Neuropathologica Communications  (2015) 3:18 Page 13 of 18(Additional file 5c), a dual-site binding AChEi, impairs
AChE-PrP complex formation. Hup8TH, which is sand-
wiched between the PAS aromatic residues Trp286 and
Tyr72 (in yellow in Additional file 5a) and the active-site
gorge residues Tyr337 and Trp86 [59], occludes the
AChE-PrP interface. These findings suggest that the pre-
cise assembly of the two oppositely charged proteins is
critically dependent on such an aromatic-rich AChE hot-
spot. The proposed AChE-PrP binding mechanism is fur-
ther supported by our results obtained using PrP fibrils
lacking the 23–99 or 100–120 N-terminal PrP segments.
The more positive charge distribution and rich aromatic
character of the 23–99 region, compared to the 100–120
region, explain the different inhibition values observed
with Hup8TH on AChE association to those fibrils. The
anti-prion activity of Hup8TH in cell culture can therefore
be ascribed to the displacement of the specific AChE-PrP
interaction, further supporting AChE role in the formation
of pathologically relevant PrP morphotypes.
A Model of AChE-binding to PrP Amyloid Fibrils
Although we do not yet have the atomic structures of full
length PrP amyloid fibrils, several biochemical and bio-
physical studies suggest that the PrP fibril spine, which
goes approximately from residue 160 to 225, stacks in-
register with parallel β-sheet strands spaced 4.8 Å along
the fibril axis [60-64]. The rest of the protein (i.e., the
non-structured N-terminus and the first α-helix) must
somehow accommodate at the periphery of the spine.
AChE crystal structure [65] and our estimation of its
molecular weight in solution (Additional file 6) suggest
the formation of a dimer with the identified interaction
hotspot in each catalytic subunit facing the opposite sides
of the complex (Additional file 5a).
On the basis of these previous structural studies and the
present results, AChE binding to PrP fibrils can be sche-
matized as follows (Figure 8). In fibrils, AChE binds to the
23–99 and 100–120 N-terminal PrP segments that should
be solvent-exposed and accessible to extrinsic biologicalfactors. However, AChE binding to these two regions of a
monomeric PrP or fibrillar PrP protomer appears to be
mutually exclusive and, thus, only one of the two sub-sites
in the PrP N-terminus can be occupied by AChE without
any steric hindrance. The 0.5:1 (AChE:PrP) stoichiometry
found for fibrils composed of truncated PrP variants can
be attributed to the particular structure of the dimeric
AChE molecule, together with the precise arrangement of
contiguous PrP molecules in a protofilament. These struc-
tural constraints could make adjacent N-terminal PrP re-
gions sterically unavailable for interaction with AChE.
Accordingly, only every second PrP protomer can be com-
plexed with an AChE catalytic subunit. In the case of full-
length fibrils, AChE might circumvent the steric overlap
to interact with contiguous PrP molecules by alternately
interacting with the two N-terminal PrP sites. This view is
reinforced by the fact that half the number of AChE cata-
lytic subunits are needed to completely saturate the bind-
ing sites of amyloid fibrils made from the two truncated
PrP variants compared to those made from the full-length
form. In addition, the intermediate association value of
AChE with full-length fibrils in the presence of Hup8TH
(30%), compared to the values obtained for the truncated
fibrils (40 and 20%), is in agreement with the different
AChE avidity for each PrP site and further supports the
proposed mechanistic association model.
Prion replication affects AChE homeostasis
We found that AChE protein levels and ACHE transcripts
are markedly increased in cerebral cortex-enriched homog-
enates from prion-infected tg338 mice compared to mock-
infected controls. Since, in this mouse model, both PrPC
distribution in the brain and PrP expression ratios between
brain and spleen are very similar to those found in conven-
tional mice [66], our results indicate that AChE homeosta-
sis is intrinsically altered upon prion replication and may be
related to compensatory mechanisms leading to ACHE
gene expression up-regulation to counteract the decrease in
AChE catalytic activity. These observations, together with
Figure 8 (See legend on next page.)
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Figure 8 Schematic representation of AChE binding to PrP amyloid fibrils. This model of AChE interaction within PrP fibrils was built using
full-length PrP and its deletion variants, and is based on the data on Hup8TH inhibition of aggregation. We considered that each PrP proto-filament
consisted of an inner spine and an outer non-structured region that includes approximately the N-terminus and the first α-helix of PrP. Due to the
specific structural features of the dimeric AChE molecule and the supposed regular structure of the PrP fibril, each AChE catalytic subunit (AChEcsub) in
the dimer may only interact with a non-contiguous PrP protomer in the protofilament. Thus, in the case of full-length PrP fibrils, AChEcsub may
associate with adjacent PrP protomers by alternately interacting with the N-terminal sites within residues 23 and 99 (in blue) and residues 100 and
120 (in red). As AChE binding to both sites in the same PrP protomer appears to be mutually exclusive, an equimolar interaction between proteins is
therefore obtained. Conversely, for fibrils formed from truncated N-terminal PrP variants (Δ100-120 and Δ23-99), which are characterized by the loss
of one of the AChE binding sites, only alternate PrP protomers may be complexed with AChE. N-terminal steric hindrance between adjacent PrP
protomers thus leads to a 0.5:1 stoichiometry. The inhibition data using Hup8TH are in agreement with the proposed model and reveal that the two
PrP N-terminal sites have similar binding mechanisms, but different avidities. The number (n) of AChEcsub (associated and free) and PrP protomers is
also shown. Further details are specified in the Discussion section.
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atic activity in the spleen, where restorative mechanisms
might be absent, indicate that AChE is not a mere bystander
but might actively participate in prion disease pathogenesis.
Furthermore, the finding that AChE homeostasis is altered
also in the spleen of infected mice and in infected cell cul-
tures, where PrPSc accumulation appears rather benign [67],
dismisses the possibility that the changes observed are the
results of neurodegeneration or an artefact due to intracere-
bral inoculation, and supports the hypothesis that they arise
in response to PrPSc accumulation. Indeed, the presence of
AChE in a variety of lymphoid and reticular cell types [68]
and particularly in follicular dendritic cells of the germinal
centers [69], the splenic cells in which prions might actively
amplify, makes plausible a causative AChE-PrP interaction
in prion pathogenesis. Nevertheless, the definitive functional
link of AChE to this mechanism still remains to be deter-
mined. While the role of AChE in peripheral prion patho-
genesis deserves further research, our findings are consistent
with previous reports on reduced AChE activity in CSF sam-
ples of CJD patients and AChE altered glycosylation pattern
in CJD CSF and brain tissue samples [32,33].
The specific mode of AChE interaction with PrP fibrils,
as detailed before, may physically obstruct acetylcholine
entry to the acylation site, and/or reduce its affinity by
charge repulsion, thus explaining the inhibition of AChE
enzymatic activity observed in the presence of fibrillar
conformers, or in different prion-infected mice tissues. As
mentioned above, the reduced AChE activity found in
cortical-enriched extracts could stimulate AChE up-
regulation in these brain areas. Alternatively, in subcor-
tical brain regions and spleen, as well as in cell cultures,
AChE complexed with PrP could become more suscep-
tible or exposed to proteolytic degradation. The lack of
compensatory mechanisms will lead to a reduction of the
AChE load. Our model is also congruent with the cell-
and tissue-dependent differences in N-terminal trimming
of PrPSc [70]. Indeed, in both MovS cells and spleen tissue,
PrPSc accumulates predominantly as trimmed species, but
still contains the 100–120 N-terminal PrP sub-site to
which AChE can bind.Conclusions
In summary, we report that AChE acts as an auxiliary mol-
ecule in PrP misfolding, leading to PrP morphotypes with
potential relevance in prion diseases. Our finding that target-
ing a druggable site in AChE blocks the formation of these
complexes is conceptually attractive and might be used for
therapeutic strategies to target prion diseases and other pro-
tein misfolding disorders. Indeed, there is strong evidence
for AChE involvement in Aβ-induced neuronal dysfunction
and Aβ fibril formation [18,19,21,22,20]. In parallel, PrP also
mediates Aβ neurotoxicity [71]. The functional involvement
of both AChE and PrP in AD, together with the AChE-PrP
assemblies described here, reveals intriguing similarities be-
tween AD and prion diseases that could bring fundamental
insights into their origins and progression. In this context,
AChE could act as a common denominator in the patho-
genesis of both diseases and its pharmacological targeting
could thus provide broader neuroprotection.Additional files
Additional file 1: Hup8TH does not interact with PrP. Thermal
unfolding of PrP in the absence (solid line) or presence (dotted line) of
Hup8TH, at equimolar concentrations, recorded by DSC.
Additional file 2: The macrostructure of the new AChE-induced
PrP fibril morphotype is different from that of classical PrP fibrils.
Negative-stained transmission electron micrographs of pre-formed PrP
fibrils alone (left panel) or mixed with AChE (right panel). The molar ratio
used was 0.5:1 (AChE:PrP). Scale bar = 100 nm.
Additional file 3: Altered digestion profile of the PK-resistant
core of PrP fibrils after AChE binding. a Silver staining following
electrophoretic separation of PrP fibrils (10.5 μM) incubated or not with
AChE (0.5 μM), before and after annealing. All fractions were PK treated.
b Densitometric analysis of the PK-resistant core of the corresponding
samples. Data are mean ± SEM values from four independent
experiments. **P < 0.05, **P < 0.005, vs. Fib PrP alone (one-way ANOVA).
ns = non significant.
Additional file 4: Cholinergic ChAT mRNA levels and the splicing
pattern of the ACHE gene are not significantly different in prion-infected
mice compared to non-infected controls. a Vertical bar chart comparing the
levels of ChAT transcripts in cerebral cortex-enriched homogenates from control
and infected mice. Values are presented as fold change relative to control mice.
Data are the mean± SEM for 5 mice/group. mRNA levels of total ChAT
transcripts were normalized to HPRT transcript expression the same cDNA
preparations. b Vertical bar chart comparing the levels of AChE T, H and R
Torrent et al. Acta Neuropathologica Communications  (2015) 3:18 Page 16 of 18transcripts, relative to total AChE transcripts, in cerebral cortex-enriched
homogenates from control and infected mice.
Additional file 5: Highly asymmetric surface charge distribution in
AChE and PrP. Schematic representation of the three-dimensional
structure and surface charges (red: negatively charged; blue: positively
charged) of two different views of AChE (a) and PrP (b). The Coulomb
potential was calculated by using the Poisson–Boltzmann equation as
implemented in the Swiss-Pdb Viewer software and the crystallographic
structures (1TQB for PrP, with a reconstituted N-terminal disordered
segment; and 3LII for the dimeric recombinant human AChE). Each dimer
consists of two AChE catalytic subunits (in light grey and in grey). The
residues involved in the interaction with Hup8TH are in yellow. An excess
of negative charge on the surface near the entrance of the AChE catalytic
gorge and the positive character of the two N-terminal PrP segments
(the 23–99 aa region is in blue and the 100–120 aa region in red) are
shown. The figure was produced using Swiss-Pdb-Viewer. (c) Structure of
the dual-binding site of the AChEi Hup8TH.
Additional file 6: AChE molecular weight estimation by
multi-wavelength light scattering coupled to size-exclusion
chromatography. AChE was loaded in a 60 × 0.78 cm TSK4000SW
column using an AKTA purifier100 FPLC device. The column exit was
connected to a homemade multi-wavelength light scattering device
with a scattering angle of 112°. The Rayleigh number leading to the
estimation of the molecular weight was determined by using carbonic
anhydrase as standard. The estimated molecular weight corresponds to
the mean value obtained from three different wavelengths: 406 nm
(violet), 450 nm (blue) and 532 nm (red).
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